Ask ten people in a grocery store line in Missouri or Ohio to name a depression treatment, and most will say the name of a pill. Almost none will say Spravato.
We know that because we paid to ask. This summer we put one plain question to 443 adults spread over ten Midwest states: had they ever come across the name Spravato, an esketamine spray the FDA cleared for depression that standard medication has not lifted? Seventy-three percent of them answered no. Another 21 percent said they recognized the word but drew a blank on what it actually does. Just 6 percent said they could explain it.
Why a marketing number is really a health number
It would be easy to read those figures as a branding problem. They are not. When two or more ordinary antidepressants have failed, that is precisely the situation this spray was approved for, and nobody in that spot can request a treatment no one has ever named to them.
How common is that spot in the Midwest? More common than the clinical label makes it sound. When we asked about personal history, 72 percent of the people we surveyed said depression, anxiety, or PTSD that routine prescriptions never fixed had touched them or someone near them. Thirty-seven percent put themselves in that group; a spouse, parent, child, or friend was the one for 22 percent; and 13 percent had lived it both ways. Only 28 percent told us nothing like that had come into their lives.
The words people use when they go looking
One open box on the questionnaire invited people to type whatever they would enter into a search bar if they wanted help. Three hundred twenty-eight of them filled it in, and reading the answers is sobering.
Some typed "help with depression." Others entered "ptsd help," "ptsd treatments," or "how to help someone with depression." There was "depression medicine alternatives," there was "therapist near me," and there was "how to cope with my anxiety." One person simply typed "someone please help me." Another left only "depressed."
Nobody typed a drug name. They described a feeling and asked for help.
The person who closes the gap is a doctor
With awareness this thin, you might guess that advertising would move people. They told us the opposite.
We asked whose word would get them to give ketamine or esketamine care a real try. Their own physician won in a landslide, named by 74 percent of respondents. Friends and relatives were a distant second at 18 percent. Veterans or first responders followed on social media earned 4 percent; a paid ad earned 2 percent, and a favorite podcast host 1 percent.
A second question pointed the same way. For a first stop, the family doctor was the pick of 56 percent of the panel, and a psychiatrist or therapist the pick of 23 percent. Twelve percent said they would start with their own online searching, 1 percent with a friend, and a candid 5 percent said they would simply be lost.
Not knowing is not the same as being against it
You might expect a hostile first reaction to an unfamiliar treatment. Mostly, we did not find one. We gave people a short phrase to react to, the idea of using ketamine to treat depression or post-traumatic stress, and let each person pick a gut response. Cautious but open was the biggest camp at 34 percent, and hopeful or curious added 18 percent. A skeptical 21 percent held back. The same share, 18 percent, said they had never come across it, and 9 percent reacted negatively.
That adds up to 51 percent leaning open and 9 percent firmly against. The dominant posture is unfamiliarity, not rejection.
What earns that openness is credentials. FDA approval, by the count of 59 percent of our sample, would weigh heavily or settle the question outright. Insurance weighed even more. Respondents placed it among their top two provider criteria at an 85 percent clip, and nearly two thirds of them, 65 percent, called coverage either decisive or a major factor for them personally.
What this means if you live here
If the usual antidepressants have let you down, or let down someone you love, here is what your neighbors' answers suggest.
- You are allowed to raise it first. Most people here were waiting for a doctor to bring it up. Saying "I have read there are options beyond another SSRI, and I want to know if any fit me" is a complete and reasonable opening.
- Know which thing you are asking about. Spravato is esketamine in spray form, cleared by the FDA for depression that earlier medicines left in place, and you use it only inside a certified office while staff keep an eye on you afterward. IV ketamine and take-home ketamine sit in a separate, looser category. If you want to see how the supervised model runs day to day, Brain Recovery Centers has a plain overview of how a Spravato treatment visit works.
- Ask the coverage question at the first visit, not after you are invested in the idea.
- Search the way you actually feel. Symptom words and plain requests for help find real resources faster than guessing a brand name.
The honest limits of this data
This is market research about awareness and decision making, not clinical evidence. It cannot predict how any one patient will respond, and it should not be read as medical advice. Whether esketamine, ketamine, or something else suits you is a call for a clinician who knows your history, your current prescriptions, and your risks.
If depression has ever brought you to the edge of thinking about suicide, please let someone know today. Three digits, 988, work by call or by text on any phone in the country. Lifeline counselors pick up around the clock, it costs nothing, and what you say stays between you.
Methodology
We commissioned and paid for this study ourselves as the publisher. Pollfish put our questions to its consumer panel, and 443 people had finished them when fieldwork closed on June 23, 2026. Participants were 18 to 64 and lived in ten Midwest states stretching from Ohio and Indiana out to Kansas, Nebraska, and Oklahoma, with Missouri, Illinois, Iowa, Wisconsin, and Minnesota between them. Each one cleared a consent screen first. Where a question allowed several answers, percentages can sum past 100. Every figure here comes from the final data set, after Pollfish finished validating the panel.